Immix Biopharma, Inc.IMMXNASDAQ
Loading
SG&A Expense Growth Under PressureDecelerating
Percentile Rank33
3Y CAGR-55.3%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-55.3%/yr
Annual compound
Percentile
P33
Within normal range
vs 3Y Ago
0.1x
Contraction
Streak
4 yr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| 2025 | 20.35% |
| 2024 | 53.68% |
| 2023 | 84.09% |
| 2022 | 228.29% |
| 2021 | 495.76% |
| 2020 | -20.68% |
| 2019 | 0.00% |